References
- Nadkarni A, Gorakshakar AC, Lu CY, et al. Molecular pathogenesis and clinical variability of β‐thalassemia syndromes among Indians. Am J Hematol. 2001 Oct;68(2):75–80. doi: 10.1002/ajh.1156
- Colah RB, Mukherjee MB, Martin S, et al. Sickle cell disease in tribal populations in India. Indian J Med Res. 2015 May;141(5):509.
- Schnog JB, Duits AJ, Muskiet FA, et al. Sickle cell disease; a general overview. Neth J Med. 2004 Nov 1;62(10):364–374.
- Lang K, Roll B, Myssina S, et al. Enhanced erythrocyte apoptosis in sickle cell anemia, thalassemia and glucose-6-phosphate dehydrogenase deficiency. Cell Physiol Biochem. 2002;12(5–6):365–372. doi: 10.1159/000067907
- Zwaal RFA, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells: a review. Blood. 1997;89(4):1121–1132. doi: 10.1182/blood.V89.4.1121
- Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood. 19961 Sep 1;88(5):1873–1880.
- Nadkarni A, Gorakshakar A, Colah R, et al. Evaluation of the clinical severity of β thalassemia homozygous patients using a phenotypic scoring system. J Chinese Clin Med. 2007;2(8):439–447.
- Italia K, Jain D, Gattani S, et al. Hydroxyurea in sickle cell disease—a study of clinico-pharmacological efficacy in the Indian haplotype. Blood Cells Mol Dis. 2009 Jan 1;42(1):25–31.
- Ware RE. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood, J Am Soc Hematology. 2010 Jul 1;115(26):5300–5311.
- Charache S, Terrin ML, Moore RD, et al. Effect of hydroxy- urea on the frequency of painful crises in sickle cell anemia. Investigators of the mul- ticenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332:1317–1322. doi: 10.1056/NEJM199505183322001
- Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood, J Am Soc Hematology. 2010 Mar 25;115(12):2354–2363.
- Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood. 1996;88(5):1873–1880. doi: 10.1182/blood.V88.5.1873.1873
- de Jong K, Emerson RK, Butler J, et al. Short survival of phosphatidylserine-exposing red blood cells in murine sickle cell anemia. Blood, J Am Soc Hematology. 2001 Sep 1;98(5):1577–1584.
- Haynes JJ, Obiako B, Hester RB, et al. Hydroxyurea attenuates activated neutrophil-mediated sickle erythrocyte membrane phosphatidylserine exposure and adhesion to pulmonary vascular endothelium. Am J Physiol Heart Circ Physiol. 2008 Jan;294(1):H379–85.
- DG A, D D, S R. Tinnitus treatment with sound stimulation during sleep. Int Tinnitus J. 2010;16:37–43.
- Schoenwaelder SM, Yuan Y, Josefsson EC, et al. Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood, J Am Soc Hematology. 2009 Jul 16;114(3):663–666.
- Bonomini M, Dottori S, Amoroso L, Arduini A, Sirolli V. Increased platelet phosphatidylserine exposure and caspase activation in chronic uremia. J Thromb Haemost. 2004 Aug 1;2(8):1275–1281.
- Covas DT, de Lucena Angulo I, Palma PV, et al. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia. Haematologica. 2004 Jan 1;89(3):273–280.